U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck's VAXNEUVANCE for Use in Infants and Children Pharmaceutical Investing
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMY, CTXS, HEPS and STNE Pharmaceutical Investing
Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults Pharmaceutical Investing
Love Pharma's Acquisition Will Offer Exclusive Partnership and License with World Renowned University to Conduct Landmark Psilocybin Study Pharmaceutical Investing
Numinus to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th Pharmaceutical Investing
AbbVie Submits Application for Risankizumab in Moderate to Severe Crohn's Disease to European Medicines Agency Pharmaceutical Investing
Merck's KEYTRUDA® Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients Withd-in-japan-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-radically-unresectab Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma Pharmaceutical Investing
FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review Pharmaceutical Investing
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, OWLT, PTON, ZG INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS Pharmaceutical Investing
